Sponsors (3)
The bill centralizes a temporary federal regime to promote FDA-led safety review and keep preterm infant formulas available nationwide, but it limits state-level rules and narrows or delays consumer legal remedies during the two-year preemption period.
Parents and caregivers of preterm/low-birth-weight infants: the bill promotes stronger federal safety oversight by enabling FDA premarket review/approval pathways for preterm infant formulas, which could raise product safety and reduce risk to vulnerable infants.
Manufacturers and retailers (and therefore parents seeking products): a two-year federal uniformity prevents a patchwork of differing state rules, reducing compliance complexity for producers and helping keep preterm formulas available across states.
Congress, state governments, and health systems: the bill requires a timely, evidence-based federal report on availability, safety, and legal gaps for preterm formulas within two years, providing policymakers with information to guide future action.
Parents and families: the bill allows manufacturers to remove state lawsuits to federal court and to seek dismissal of pending state enforcement actions during the two-year period, which could delay or limit consumers' ability to obtain timely remedies after harm.
Plaintiffs (injured families) and local advocates: the bill applies a high clear-and-convincing burden of proof and a narrow willful-misconduct exception for certain suits, making it harder for harmed consumers to win liability or recover damages from manufacturers.
State governments and residents in states seeking stricter protections: the bill preempts state authority for two years to impose stricter safety or labeling rules for preterm formulas, potentially delaying stronger local protections where states would prefer them.
Based on analysis of 2 sections of legislative text.
Requires an HHS/FDA study of preterm infant formula regulation and safety, temporarily preempts differing state/local requirements for two years, and permits federal removal of certain state actions.
Requires the Department of Health and Human Services, through the FDA Commissioner, to study the availability, safety, and legal landscape for preterm infant formula and to report recommendations to Congress within two years. For two years after enactment, it temporarily preempts State or local requirements that differ from specified Federal requirements for preterm infant formula, while preserving narrow State civil or criminal claims for willful misconduct (with a heightened burden of proof) and permitting removal of certain cases to federal court.
Introduced March 24, 2025 by Diana Harshbarger · Last progress March 24, 2025